Merck has reported that its experimental cancer drug sacituzumab tirumotecan helped patients with advanced stomach and oesophageal cancers live longer than standard chemotherapy in a late-stage trial — the first drug of its kind to do so.
Key Points
- Merck sac-TMT stomach cancer — sacituzumab tirumotecan (sac-TMT) met the primary endpoint of overall survival in the Phase 3 TroFuse-015 trial, Merck said on Friday 20 November 2026.
- The trial enrolled 473 patients whose cancer could not be removed by surgery and whose disease had progressed after at least two earlier treatments.
- Sac-TMT is the first TROP2-directed antibody-drug conjugate to improve overall survival versus physician’s choice of chemotherapy in this population.
- It did not meet the secondary endpoint of progression-free survival, though the objective response rate showed a nominal improvement; no new safety concerns were reported.
- Detailed data will be presented at a future medical meeting and shared with regulators.

Merck — known as MSD outside the United States and Canada — announced the results on Friday, calling them a milestone for patients with gastroesophageal cancers that have run out of options. These are cancers of the stomach and the oesophagus, and once they have spread and stopped responding to treatment, the outlook is bleak. Patients in this trial had already been through at least two earlier lines of treatment, and their cancer could not be removed by surgery.
The TroFuse-015 trial compared sac-TMT with chemotherapy chosen by each patient’s own physician — trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Against that real-world comparison, sac-TMT helped patients live longer, meeting the trial’s primary endpoint of overall survival. Merck disclosed no detailed data, saying the full results will be presented at a future medical meeting and shared with regulators.
How the drug works
Sac-TMT is an antibody-drug conjugate, a type of treatment designed to deliver cancer-killing drugs directly to tumour cells while minimising damage to healthy tissue. It works by targeting TROP2, a protein found on the surface of many cancer cells, and using an antibody as a delivery vehicle to carry a potent chemotherapy payload straight to the tumour. The idea is to concentrate the attack where it is needed and spare the rest of the body — a precision approach that has become one of the most closely watched areas of cancer research.
Merck licensed sac-TMT from China’s Kelun-Biotech for markets outside Greater China, and the drug sits at the centre of the company’s TroFuse programme. This is the second positive Phase 3 readout from that programme, which has 18 ongoing Phase 3 trials across tumour types including lung, breast, bladder, cervical, gastric, endometrial and ovarian cancers.
A first — with a caveat
The result matters because sac-TMT is the first TROP2-directed antibody-drug conjugate to improve overall survival compared with physician’s choice of chemotherapy in this population. Overall survival — how long patients actually live — is the hardest endpoint in cancer medicine, and the one that matters most to patients and their families.
But the picture is not uncomplicated. The trial did not meet its secondary endpoint of progression-free survival — the length of time before the cancer starts growing again — as assessed by independent review, although the objective response rate showed a nominal improvement. No new safety concerns were reported. Until the detailed data are presented, doctors will not know how large the survival benefit is, or which patients gained the most.
What happens next
The next step is the medical meeting where Merck will present the full results, and the discussions with regulators that will decide whether sac-TMT can move towards approval. For patients with advanced stomach and oesophageal cancers who have run out of standard options, the result offers something that has been in short supply: a new treatment shown, in a rigorous trial, to help people live longer.
For background on Merck’s cancer work, see our report on Moderna and Merck reporting breakthrough results for a personalised mRNA melanoma vaccine, and on daily sugary beverage consumption being linked to increased gastric cancer risk. More in our Health section.
Sources: Reuters, “Merck’s drug prolongs survival in advanced stomach, esophageal cancers in trial” (https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-drug-prolongs-survival-advanced-stomach-esophageal-cancers-trial-2026-11-20/); Business Wire, “Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma” (https://www.businesswire.com/news/home/20261120719582/en/Merck-Announces-TroFuse-015-Trial-Evaluating-Sacituzumab-Tirumotecan-Sac-TMT-Met-Primary-Endpoint-of-Overall-Survival-OS-in-Third-Line-or-Later-Locally-Advanced-Unresectable-or-Metastatic-Gastroesophageal-Adenocarcinoma)
